Yourgene Health Launches IONA Care+ Non-invasive Prenatal Testing Service
Offers expectant parents fully comprehensive prenatal screening test for genetic conditions, including microdeletions
Manchester, UK, 13 February 2025: Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, today announced the launch of IONA® Care+, a fully comprehensive non-invasive prenatal screening service for genetic conditions, in the UK. The service will utilise Yourgene’s IONA® Nx NIPT Workflow to deliver safe, fast and accurate non-invasive prenatal testing (NIPT) results. This reduces the need for invasive tests and the associated risks, while helping to decrease stress and anxiety for expectant parents.
IONA Care+ builds upon Yourgene Genomic Services’ current NIPT offering, providing an extensive menu-based approach where expectant parents can select screening tests to measure the likelihood that a fetus is affected by a genetic condition. Yourgene’s NIPT Service screening menu includes Down’s, Edwards’ and Patau’s syndromes (trisomy 21, 18 and 13, respectively) and other autosomal aneuploidies and monosomies as well as sex chromosomal aneuploidies, such as Turner, Triple X, Klinefelter and Jacobs syndromes. With the launch of IONA Care+, the comprehensive menu now includes clinically relevant microdeletion syndromes, namely DiGeorge Syndrome, Prader-Willi, Angelman, 1p36 deletion, Cri-du-Chat and Wolf-Hirschhorn Syndrome.
NIPT is performed on a small maternal blood sample from as early as 10 weeks gestation and uses next generation sequencing to estimate the risk of a fetus being affected by a genetic condition. Expectant parents and healthcare professionals can choose the most suitable NIPT service from three different clinical options to suit their individual needs: the IONA test for the three most common trisomies including Down’s Syndrome, the IONA Care which includes trisomies and sex chromosome aneuploidies, and now the IONA Care+ which includes clinically relevant microdeletions. Screening results will be available from Yourgene Genomic Services’ laboratories in Manchester, UK within 3–5 working days via their local midwife or private clinic. The test is only available for singleton and monochorionic twin pregnancies.
Lyn Rees, CEO of Novacyt, said: “We are pleased to announce our newest service — the most comprehensive clinical menu in our portfolio of screening tests offered to pregnant women by our Genomic Services’ laboratories.
IONA Care+ is the extension of our NIPT Service portfolio running in our Manchester Service Laboratory. Yourgene Health launched the first CE-IVD NIPT in 2015, with the original IONA test, so it’s great to see us continuing to enhance the NIPT landscape 10 years later.
We are very proud, once again, to be contributing to patient care where it’s needed and continue to work with healthcare professionals to provide high-quality and safe screening for pregnant women during their pregnancies.”
For more information about Yourgene’s IONA Care+ Service, please visit: https://yourgenehealth.com/our-services/nipt-sample-service/nipt-service-for-healthcare-professionals/prenatal-screening-service/iona-care-plus-comprehensive-menu
